On November 21, 2022, Thiogenesis Therapeutics, Corp. closed the transaction. The company issued 10,619,400 common shares for gross proceeds of CAD 5.3097 million. The transaction was oversubscribed. All securities issued and issuable in connection with the Offering will be subject to a 4-month plus one day hold period ending on March 19, 2023. The transaction has received conditional acceptance from the TSX Venture Exchange but remains subject to receipt of final acceptance. The company paid CAD 352,750 in finder's fees and issued 675,500 in non transferable Finder's Options.

On November 23, 2022, the company announced that TSX Venture Exchange has accepted for filing documentation of the non-brokered private placement. The transaction included participation from 82 placees and total pro group involvement was for 980,000 by 11 pro groups.